RIGEL PHARMACEUTICALS INC - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring on May 14, 2026, at the Company's 2026 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes regarding director elections, equity plan amendments, executive compensation, and auditor ratification.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan approvals.
Material Changes and Corporate Actions
- Equity Plan Amendments: Stockholders approved amendments to increase the share pool for two key plans:
- 2018 Equity Incentive Plan: Added 500,000 shares to the authorized issuance limit.
- 2000 Employee Stock Purchase Plan (ESPP): Added 360,000 shares to the authorized issuance limit.
- Director Elections: Three directors were elected to serve until the 2029 Annual Meeting:
- Alison Hannah, M.D. (9,202,113 For; 1,469,709 Withheld)
- Walter Moos, Ph.D. (10,436,673 For; 242,736 Withheld)
- Raul Rodriguez (10,486,503 For; 192,614 Withheld)
- Executive Compensation: The "Say-on-Pay" proposal was approved on an advisory basis (9,013,480 For; 1,291,609 Against).
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026 (12,590,773 For; 1,506,852 Against).
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. It strictly reports the results of the shareholder vote.
Investor Verification Checklist
- Verify the total number of shares now authorized under the amended 2018 Equity Incentive Plan and 2000 ESPP by reviewing the definitive Proxy Statement filed on April 3, 2026.
- Review the specific terms of the equity plan amendments (Appendix A and B of the Proxy Statement) to understand vesting schedules and eligibility criteria.
- Confirm the tenure of the newly elected directors, which extends through the 2029 Annual Meeting.
- Note the significant number of broker non-votes (3,406,029) across all proposals, indicating shares held in street name where brokers did not have discretionary voting authority.